MX355050B - Derivados de quinolina antibacterianos. - Google Patents
Derivados de quinolina antibacterianos.Info
- Publication number
- MX355050B MX355050B MX2014013056A MX2014013056A MX355050B MX 355050 B MX355050 B MX 355050B MX 2014013056 A MX2014013056 A MX 2014013056A MX 2014013056 A MX2014013056 A MX 2014013056A MX 355050 B MX355050 B MX 355050B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- quinoline derivatives
- pharmaceutically acceptable
- treatment
- bacterial infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a derivados de quinolina sustituidos novedosos de acuerdo con la fórmula general (la) o la fórmula (Ib): (ver Fórmula) que incluyen cualquiera de sus formas estereoquímicamente isoméricas, una de sus sales farmacéuticamente aceptables, uno de sus N-óxidos o uno de sus solvatos; los compuestos reivindicados son útiles para el tratamiento de una infección bacteriana; también se reivindica una composición que comprende un portador farmacéuticamente aceptable y, como principio activo, una cantidad terapéuticamente eficaz de los compuestos reivindicados, el uso de los compuestos o las composiciones reivindicados para la elaboración de un medicamento para el tratamiento de una infección bacteriana y un proceso para preparar los compuestos reivindicados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12165934 | 2012-04-27 | ||
PCT/EP2013/058703 WO2013160435A1 (en) | 2012-04-27 | 2013-04-26 | Antibacterial quinoline derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014013056A MX2014013056A (es) | 2014-12-10 |
MX355050B true MX355050B (es) | 2018-04-02 |
Family
ID=48227271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014013056A MX355050B (es) | 2012-04-27 | 2013-04-26 | Derivados de quinolina antibacterianos. |
Country Status (15)
Country | Link |
---|---|
US (1) | US9133167B2 (es) |
EP (1) | EP2841425B1 (es) |
JP (1) | JP6153604B2 (es) |
KR (1) | KR102110355B1 (es) |
CN (1) | CN104254527B (es) |
AU (1) | AU2013254674B2 (es) |
CA (1) | CA2869718C (es) |
DK (1) | DK2841425T3 (es) |
EA (1) | EA035443B1 (es) |
ES (1) | ES2576491T3 (es) |
HK (1) | HK1205514A1 (es) |
IN (1) | IN2014MN02364A (es) |
MX (1) | MX355050B (es) |
PL (1) | PL2841425T3 (es) |
WO (1) | WO2013160435A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA038350B1 (ru) * | 2012-04-27 | 2021-08-12 | Янссен Фармацевтика Нв | Антибактериальные хинолиновые производные |
WO2016020836A1 (en) * | 2014-08-06 | 2016-02-11 | Novartis Ag | Quinolone derivatives as antibacterials |
US10508097B2 (en) * | 2016-03-07 | 2019-12-17 | The Global Alliance For Tb Drug Development, Inc. | Antibacterial compounds and uses thereof |
KR102574912B1 (ko) * | 2016-08-17 | 2023-09-07 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
US11857352B2 (en) | 2016-09-06 | 2024-01-02 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2270123A1 (en) | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
US6103905A (en) | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
GB0118238D0 (en) * | 2001-07-26 | 2001-09-19 | Smithkline Beecham Plc | Medicaments |
PL222801B1 (pl) | 2002-07-25 | 2016-09-30 | Janssen Pharmaceutica Nv | Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je |
AP2188A (en) * | 2004-01-23 | 2010-12-14 | Janssen Pharmaceutica Nv | Substituted quinolines and their use as mycobacterial inhibitors. |
PT1711181E (pt) | 2004-01-23 | 2009-12-29 | Janssen Pharmaceutica Nv | Derivados quinolina e sua utilização como inibidores micobacterianos |
AU2005210036B2 (en) | 2004-01-29 | 2010-12-23 | Janssen Pharmaceutica N.V. | Quinoline derivatives for use as mycobacterial inhibitors |
EP1753427B1 (en) | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
WO2005123081A2 (en) | 2004-06-22 | 2005-12-29 | Janssen Pharmaceutica N.V. | (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia |
DK1797115T3 (en) | 2004-09-28 | 2017-10-02 | Janssen Pharmaceutica Nv | BACTERIAL ATP SYNTHASE BINDING DOMAIN. |
EE05394B1 (et) | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
CA2528849C (en) | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
JO2752B1 (en) | 2005-06-28 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
BRPI0613999B8 (pt) | 2005-06-28 | 2021-05-25 | Janssen Pharmaceutica Nv | uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto |
JO3270B1 (ar) | 2005-06-28 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات كوينولين بصفة عوامل مضادة للبكتيريا |
JO3077B1 (ar) | 2005-07-28 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينولين مضادة للبكتيريا |
JO2855B1 (en) | 2005-08-03 | 2015-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
JO2952B1 (en) | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
JO2837B1 (en) | 2005-08-03 | 2014-09-15 | جانسن فارمسيتكا ان في | Quinoline derivatives acting as antibacterial agents |
JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
JO2970B1 (en) | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
JO2685B1 (en) | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان في | Quinoline antibacterial derivatives |
JO2684B1 (en) | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان في | Quinoline antibacterial derivatives |
JO3271B1 (ar) | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
JO2725B1 (en) | 2006-12-06 | 2013-09-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
US20110059948A1 (en) * | 2008-01-14 | 2011-03-10 | Jyoti Chattopadhyaya | Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivatives as anti-mycobacterial agents |
EA038350B1 (ru) * | 2012-04-27 | 2021-08-12 | Янссен Фармацевтика Нв | Антибактериальные хинолиновые производные |
-
2013
- 2013-04-26 ES ES13719524.4T patent/ES2576491T3/es active Active
- 2013-04-26 CA CA2869718A patent/CA2869718C/en active Active
- 2013-04-26 EP EP13719524.4A patent/EP2841425B1/en active Active
- 2013-04-26 PL PL13719524.4T patent/PL2841425T3/pl unknown
- 2013-04-26 KR KR1020147031040A patent/KR102110355B1/ko active IP Right Grant
- 2013-04-26 US US14/391,045 patent/US9133167B2/en active Active
- 2013-04-26 IN IN2364MUN2014 patent/IN2014MN02364A/en unknown
- 2013-04-26 DK DK13719524.4T patent/DK2841425T3/en active
- 2013-04-26 MX MX2014013056A patent/MX355050B/es active IP Right Grant
- 2013-04-26 AU AU2013254674A patent/AU2013254674B2/en active Active
- 2013-04-26 WO PCT/EP2013/058703 patent/WO2013160435A1/en active Application Filing
- 2013-04-26 JP JP2015507549A patent/JP6153604B2/ja active Active
- 2013-04-26 CN CN201380021790.5A patent/CN104254527B/zh active Active
- 2013-04-26 EA EA201491982A patent/EA035443B1/ru not_active IP Right Cessation
-
2015
- 2015-06-29 HK HK15106132.9A patent/HK1205514A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IN2014MN02364A (es) | 2015-08-14 |
KR20150013156A (ko) | 2015-02-04 |
CA2869718C (en) | 2021-05-11 |
AU2013254674B2 (en) | 2017-02-02 |
CN104254527A (zh) | 2014-12-31 |
JP6153604B2 (ja) | 2017-06-28 |
AU2013254674A1 (en) | 2014-10-16 |
CA2869718A1 (en) | 2013-10-31 |
DK2841425T3 (en) | 2016-06-27 |
EP2841425A1 (en) | 2015-03-04 |
CN104254527B (zh) | 2017-05-31 |
EP2841425B1 (en) | 2016-03-23 |
PL2841425T3 (pl) | 2016-10-31 |
JP2015518003A (ja) | 2015-06-25 |
EA201491982A1 (ru) | 2015-02-27 |
US20150065502A1 (en) | 2015-03-05 |
KR102110355B1 (ko) | 2020-05-14 |
MX2014013056A (es) | 2014-12-10 |
EA035443B1 (ru) | 2020-06-17 |
ES2576491T3 (es) | 2016-07-07 |
WO2013160435A1 (en) | 2013-10-31 |
US9133167B2 (en) | 2015-09-15 |
HK1205514A1 (en) | 2015-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3271B1 (ar) | مشتقات الكوينولين المضادة للجراثيم | |
MY188960A (en) | Cyclic boronic acid ester derivatives and therapeutic uses thereof | |
UA101305C2 (ru) | Антибактериальные производные хинолина | |
MX2014013056A (es) | Derivados de quinolina antibacterianos. | |
HK1137431A1 (en) | Antibacterial quinoline derivatives | |
JO2970B1 (en) | Quinoline antibacterial derivatives | |
WO2013106756A3 (en) | Antimicrobial agents | |
JO2685B1 (en) | Quinoline antibacterial derivatives | |
MX358506B (es) | Derivados de quinolina antibacterianos. | |
UA101307C2 (ru) | Антибактериальные производные хинолина | |
NZ700507A (en) | Pyrimidine derivatives for the treatment of bacterial diseases | |
MX2015012575A (es) | Novedosos derivados de acrilamida como agentes contra la malaria. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |